
U.S. Peripheral Intravenous Catheters Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The U.S. peripheral intravenous catheters market was valued at USD 1.9 billion in 2024. The market is expected to reach from USD 2.1 billion in 2025 to USD 3.8 billion in 2034, growing at a CAGR of 6.7% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the rising burden of chronic and lifestyle diseases, increasing number of hospitalizations and emergency care procedures, expansion of outpatient and home infusion therapy, and advancements in catheter design and safety features, among other contributing factors.

Peripheral intravenous catheters (PIVCs) are small, flexible tubes inserted into peripheral veins, usually in the hand or arm, to deliver medications, fluids, or nutrients directly into the bloodstream. They provide short-term venous access in hospitals, emergency care, and outpatient settings. PIVCs are commonly used for treatments such as hydration, antibiotic therapy, pain management, and blood sampling.
The major contributors to the U.S. peripheral intravenous catheters market are Becton, Dickinson and Company, B. BRAUN, ICU Medical, TERUMO, and Teleflex. These companies strengthen their competitive position by ongoing product originality, worldwide market presence, and huge allocations in the research and development area.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2024 |
| Market Size in 2024 | USD 1.9 Billion |
| Market Size in 2025 | USD 2.1 Billion |
| Forecast Period 2025 - 2034 CAGR | 6.7% |
| Market Size in 2034 | USD 3.8 Billion |
| Key Market Trends | |
| Drivers | Impact |
| Rising incidence of chronic diseases and cancer | The growing number of patients with chronic illnesses and cancer has increased demand for frequent IV therapies, driving PIVC utilization in hospitals and outpatient settings. |
| Increasing hospital admissions and outpatient procedures | Higher surgical volumes and procedural care have expanded the need for short-term venous access, supporting market growth. |
| Preference for peripheral IVs over central lines for short-term access | Clinicians increasingly favor PIVCs for safer, less invasive, and cost-effective short-term treatments, boosting adoption. |
| Technological improvements in catheter materials and designs | Innovations like anti-microbial coatings, flexible materials, and safety-engineered designs have enhanced patient outcomes, encouraging wider use. |
| Pitfalls & Challenges | Impact |
| Risk of catheter-related bloodstream infections (CRBSIs) and complications | Infection risks remain a significant concern, limiting prolonged use and necessitating stringent monitoring, which can restrain market expansion. |
| Strict regulatory requirements and lengthy approvals | Compliance with FDA standards and approval timelines slows product launches and increases development costs, affecting market pace. |
| Opportunities: | Impact |
| Development of antimicrobial/coated and biofilm-resistant catheters | Emerging catheter technologies with infection-prevention features are expected to reduce CRBSIs, enhance patient safety, and drive higher adoption. |
| Market Leaders (2024) | |
| Market Leaders |
~ 25% Market share |
| Top Players |
Collective market share in 2024 is ~ 75% |
| Competitive Edge |
|
| Regional Insights | |
| Largest Market | South Atlantic |
| Fastest growing market | Pacific Central |
| Emerging states | Illinois, Texas, Maryland, Connecticut, Tennessee |
| Future outlook |
|
The market has increased from USD 1.5 billion in 2021 and reached USD 1.8 billion in 2023, with the historic growth rate of 8.5%. The growth is attributed to the rising prevalence of chronic diseases requiring frequent intravenous therapies, increasing surgical and hospitalization rates, and advancements in catheter materials and safety features that enhance patient comfort and reduce infection risks.
Moreover, the increasing incidence of cardiovascular diseases, cancer, diabetes, and renal disorders in the U.S. drives higher hospital admissions and extended treatments requiring intravenous (IV) therapy. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2022, cardiovascular diseases affected 18.2 million adults, while the American Cancer Society reported 1.9 million new cancer cases in 2023.
The National Diabetes Statistics Report 2023 indicated that 37.3 million Americans have diabetes. Peripheral IV catheters play a vital role in drug administration, hydration, and chemotherapy. The aging population's susceptibility to chronic diseases increases the reliance on peripheral IV catheters, with the U.S. Census Bureau projecting that adults aged 65 and older will reach 77 million by 2024, supporting continuous market expansion.
Furthermore, technological developments have introduced needle-stick injury prevention systems, closed IV catheter systems, and antimicrobial-coated catheters. These innovations improve insertion success, patient comfort, and infection control outcomes. Hospitals increasingly adopt safety-engineered catheters to reduce catheter-related bloodstream infections (CRBSIs) and meet nursing safety protocols. Enhanced device reliability drives product replacement demand as well.
The market is experiencing several notable trends that are shaping its growth and development. Factors such as the growth of home and ambulatory IV therapy, the shift toward safety-engineered and antimicrobial catheters, the integration of smart and technology-enhanced devices, and the increased focus on minimally invasive and patient-friendly designs, among others, are collectively driving industry growth.

Based on the product, the U.S. peripheral intravenous catheters market is segmented into short PIVC and integrated/closed PIVC. The short PIVC segment has asserted its dominance in the market by securing a significant market share of 63.9% in 2024 owing to its widespread use in hospitals and outpatient settings, ease of insertion, cost-effectiveness, and suitability for short-to medium-term intravenous therapies across diverse patient populations. The segment is expected to exceed USD 2.4 billion by 2034, growing at a CAGR of 6.5% during the forecast period.
On the other hand, the integrated/closed PIVC segment is expected to grow with a CAGR of 7%. The growth of this segment is driven by increasing demand for safety-engineered, needle-free systems that reduce contamination and needlestick injuries, along with regulatory emphasis on healthcare worker and patient safety.
Based on technology, the U.S. peripheral intravenous catheters market is segmented into safety PIVC and conventional PIVC. The safety PIVC segment dominated the market in 2024, accounting for USD 1.4 billion and is anticipated to grow at a CAGR of 6.8% during the forecast period.
Based on lumen, the U.S. peripheral intravenous catheters market is segmented into single lumen, double lumen, and multi-lumen. The single lumen segment dominated the market in 2024, accounting for USD 790.4 million and is anticipated to grow at a CAGR of 6.5% during the forecast period.

Based on end use, the U.S. peripheral intravenous catheters market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 54.3% in 2024 and is expected to reach USD 2 billion within the forecast period.

The South Atlantic zone dominated the U.S. peripheral intravenous catheters market with the leading market share of 19.4% in 2024.
The Pacific Central peripheral intravenous catheters market accounted for USD 252.9 million in 2024 and is anticipated to show lucrative growth over the forecast period.
The Northeast peripheral intravenous catheters market is anticipated to grow at the highest CAGR of 7.8% during the analysis timeframe.
The market is highly competitive, driven by innovation, safety features, and hospital procurement preferences. Companies focus on developing advanced safety-engineered catheters, needle-free connectors, and smart PIVCs to enhance patient safety and procedural efficiency.
Leading industry players such as Becton, Dickinson and Company, B. BRAUN, ICU Medical, TERUMO, and Teleflex hold around 75% of the market share in the competitive U.S. landscape, reflecting strong brand recognition, extensive distribution networks, and trusted clinical performance.
In addition to product innovation, companies compete through strategic partnerships with hospitals, outpatient centers, and home healthcare providers. Emphasis on regulatory compliance, cost-effectiveness, and training for healthcare professionals further strengthens market positioning. Smaller and regional players target niche applications or cost-sensitive segments, providing tailored solutions to outpatient clinics and ambulatory surgical centers.
Continuous R&D investment, focus on infection control, and adoption of digital health-enabled catheters are expected to shape competitive dynamics and maintain high entry barriers for new entrants.
A few of the prominent players operating in the U.S. peripheral intravenous catheters industry include:
BD is a market leader in safety-engineered PIVCs, offering products like Nexiva and Insyte Autoguard that reduce needlestick injuries and improve patient safety. Its strong R&D capabilities and global distribution network ensure high adoption across hospitals, outpatient centers, and home healthcare.
B. Braun’s PIVCs, such as the Introcan Safety series, emphasize passive safety mechanisms and ergonomic design to minimize occupational hazards. The company’s focus on infection control, clinical training, and integration with hospital workflows strengthens its position in both hospital and outpatient markets.
ICU Medical specializes in advanced IV therapy solutions with integrated safety features, including closed-system catheters and needle-free connectors. Its products are widely adopted in critical care and infusion therapy settings due to reliability, compliance with regulatory standards, and ease of use for healthcare professionals.
Market, By Product
Market, By Technology
Market, By Lumen
Market, By End Use
The above information is provided for the following zones and states:
Key players include Access Vascular, AngioDynamics, B. Braun, Becton, Dickinson and Company, DELTA MED, ICU Medical, Lineus Medical, MEDEREN, MedSource Labs, and Retractable Technologies.
Key trends include the adoption of safety-engineered and antimicrobial-coated catheters, the integration of smart technology, and a focus on minimally invasive, patient-friendly designs.
The safety PIVC segment generated USD 1.4 billion in 2024 and is expected to grow at a CAGR of 6.8% during the forecast period.
The South Atlantic zone led the market with a 19.4% share in 2024, driven by a high concentration of healthcare facilities and increasing adoption of advanced medical devices.
The short PIVC segment accounted for 63.9% of the market share in 2024, driven by its widespread use in hospitals and outpatient settings.
The market size was valued at USD 1.9 billion in 2024, with a CAGR of 6.7% projected through 2034, driven by the rising prevalence of chronic diseases, increasing hospitalizations, and advancements in catheter technology.
The market is expected to reach USD 3.8 billion by 2034, fueled by the expansion of outpatient and home infusion therapies and the adoption of safety-engineered devices.
The market is anticipated to reach USD 2.1 billion in 2025.


